Figure 1 Treatment-induced resistance and evolution to lineage crisis

Slides:

Advertisements

Similar presentations

Most Random Gene Expression Signatures are Significantly Associated with Breast Cancer Outcome Venet, et al. PLoS Computational Biology, 2011 Molly Carroll.

Advertisements

Acquisition of tumour multidrug resistance inevitable in most advanced solid tumours – Failing to cure the majority of advanced solid tumours – Declining.

Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.

MiRNA-drug resistance mechanisms Summary Hypothesis: The interplay between miRNAs, signaling pathways and epigenetic and genetic alterations are responsible.

Group 6 GERMS, DRUGS and GENES: Revealing mechanisms of gene expression using antibiotics Alejandro Calderon-Urrea Nancy Connell Nigel Crawford Mamta Rawat.

Dr. Ziad W Jaradat Cancer Stem Cells. Recently biologically distinct and relatively rare populations of tumor-initiating cells have been identified in.

Dr Gihan E-H Gawish, MSc, PhD Molecular Biology and Clinical Biochemistry KSU Cytogenetics Understanding the Disease Progression Process, Classical and.

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.

Predicting Subsequent Response to Hormone Therapy Following First-line Androgen Deprivation in Advanced Prostate Cancer S. Turner H. Gurney V. Gebski M.

Greg Brooke Molecular Oncology. Prostate Cancer - Leading Cause of Cancer- related death in men - Growth dependent on androgens - Therapy targets androgen.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

Genomic Medicine Rebecca Tay Oncology Registrar. What is Genomic Medicine? personalised, precision or stratified medicine.

AR-V7 Splice Variant in Prostate Cancer : Taking Centre Stage

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Figure 1 The heterogenous landscape of triple-negative breast cancer

Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand Bannakij Lojanapiwat, Choosak Pripatnanont,

David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.

Figure 1 Key elements of cancer-related inflammation

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Risk-adapted and response-adapted

Figure 1 Cellular processes involved in cancer development

Figure 5 Schematic illustration of different clinical trial designs

Figure 4 The mechanistic link between the epithelial-to-mesenchymal

Figure 3 The contribution of the tumour microenvironment

MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review

Figure 3 Monitoring clonal evolution using liquid biopsies

Advances in the Treatment of Metastatic Prostate Cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance.

Figure 1 Classical and non-classical models of the cell cycle in RB1-proficient cells Figure 1 | Classical and non-classical models of the cell cycle in.

Figure 3 The cell cycle and the role of CDK4/6 inhibition

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 4 Possible combination therapies CDK4/6 inhibitors

Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy W. Nathaniel Brennen, John T. Isaacs Cancer Cell

Figure 1 CAR-T-cell design

Figure 1 A schematic representation of the HER2 signalling pathway

Colon Cancer Stem Cells: Promise of Targeted Therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Figure 2 Differences between MC and AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Selective estrogen receptor modulation

Figure 1 The dynamic nature of resistance mechanisms can be

Figure 1 Morphological and physiological changes

Cellular Origin of Androgen Receptor Pathway-Independent Prostate Cancer and Implications for Therapy W. Nathaniel Brennen, John T. Isaacs Cancer Cell

Figure 3 The yin and yang of tumour-associated

Figure 5 The mechanism underlying epithelial-to-mesenchymal

Figure 2 The patterns of epithelial-to-mesenchymal

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Approaches to improve CAR-T-cell therapy

Volume 22, Issue 6, Pages (December 2012)

Figure 2 Dominance of the cell-extrinsic effects of autophagy

Figure 2 Frequency and overlap of alterations

Figure 2 Variations between planned and delivered doses of radiation

Figure 6 Proposed model of clonal evolution in multiple myeloma

Figure 2 Effect of chromosomal instability tolerance

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Proposed spiral model for prostate cancer progression.

Figure 3 Determination of the primary site

Gene Regulation and Mutation

Figure 4 Molecular signalling and immunological

Hariharan Easwaran, Hsing-Chen Tsai, Stephen B. Baylin Molecular Cell

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Location of the ER mutations and frequencies per cohort.

Figure 1 Infection and resistance in urological practice

Presentation transcript:

Figure 1 Treatment-induced resistance and evolution to lineage crisis Figure 1 | Treatment-induced resistance and evolution to lineage crisis. a | Treatment-naive bacterial populations are composed largely of antibiotic-sensitive subpopulations, but might contain small numbers of mutant bacteria harbouring genetically acquired mechanisms of resistance (left). Upon antibiotic treatment, widespread death typically occurs; however, upon drug removal or during a 'drug holiday', resistant bacterial clones expand, potentially taking over both sensitive and resistant populations. Additional antibiotic treatments can lead to further genetic alterations and to the selection of a population of multidrug resistant microorganisms, which would then have the option to increase fitness by becoming a drug-sensitive population. b | Treatment-naive prostate cancers are composed mostly of cells with high levels of androgen receptor (AR-hi) activity (left) for which radiation and/or androgen deprivation therapy (ADT) typically result in a pronounced treatment response that includes primary tumour regression and reduced prostate-specific antigen (PSA) secretion. Primary or metastatic foci can recur, often leading to expansion of the AR-hi tumour bulk and elevated serum PSA levels. Follow-up treatment can include androgen receptor (AR)-targeted therapies or chemotherapies that would drive cells to adapt by dedifferentiation, thus facilitating an increase in neuroendocrine (NE) gene expression. Continued ADT and taxane-based treatment ultimately selects populations that have undergone de novo loss-of-function mutations in key cell-cycle regulators. Ultimately, the accumulation of these genetic and epigenetic events leads to a clinically detectable lineage crisis. c | Triple-negative breast cancer (TNBC) is an undifferentiated disease characterized by low expression of oestrogen receptor (ER), progesterone receptor (PR), and an absence of HER2 amplification. BCa, breast cancer; EMT, epithelial-to-mesenchymal transition; mCRPC, metastatic castration-resistant prostate cancer; MET, mesenchymal-to-epithelial transition; NEPC, neuroendocrine prostate cancer; PCa, prostate cancer; REST, RE-1 silencing transcription factor; SRRM4, serine/arginine repetitive matrix protein 4. Roubaud, G. et al. (2016) Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.181